中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2014年
2期
55-58
,共4页
枫蓼肠胃康胶囊%美沙拉嗪%溃疡性结肠炎%临床疗效
楓蓼腸胃康膠囊%美沙拉嗪%潰瘍性結腸炎%臨床療效
풍료장위강효낭%미사랍진%궤양성결장염%림상료효
Fengliaochangweikang capsule%Mesalazine%Ulcerative colitis%Clinical effect
目的 探讨枫蓼肠胃康胶囊联合美沙拉嗪对反复发作型溃疡性结肠炎的临床疗效.方法 将2008年3月至2013年3月在原平市第一人民医院治疗的57例慢性反复发作型溃疡性结肠炎患者分为治疗组和对照组,对照组每天口服美沙拉嗪,治疗组采用枫蓼肠胃康胶囊联合美沙拉嗪.观察两组患者的临床疗效、临床症状缓解情况、肠镜、组织学检查结果以及不良反应发生情况.结果 治疗组临床疗效、临床症状缓解情况、肠镜、组织学检查结果均显著优于对照组(P<0.05);治疗组总不良反应发生率为32.26%,明显低于对照组(53.85%),两组比较差异有统计学意义(x2=9.506,P<0.05).结论 枫蓼肠胃康胶囊联合美沙拉嗪治疗慢性反复发作型溃疡性结肠炎疗效优于单用美沙拉嗪,且安全性高,值得临床推广应用.
目的 探討楓蓼腸胃康膠囊聯閤美沙拉嗪對反複髮作型潰瘍性結腸炎的臨床療效.方法 將2008年3月至2013年3月在原平市第一人民醫院治療的57例慢性反複髮作型潰瘍性結腸炎患者分為治療組和對照組,對照組每天口服美沙拉嗪,治療組採用楓蓼腸胃康膠囊聯閤美沙拉嗪.觀察兩組患者的臨床療效、臨床癥狀緩解情況、腸鏡、組織學檢查結果以及不良反應髮生情況.結果 治療組臨床療效、臨床癥狀緩解情況、腸鏡、組織學檢查結果均顯著優于對照組(P<0.05);治療組總不良反應髮生率為32.26%,明顯低于對照組(53.85%),兩組比較差異有統計學意義(x2=9.506,P<0.05).結論 楓蓼腸胃康膠囊聯閤美沙拉嗪治療慢性反複髮作型潰瘍性結腸炎療效優于單用美沙拉嗪,且安全性高,值得臨床推廣應用.
목적 탐토풍료장위강효낭연합미사랍진대반복발작형궤양성결장염적림상료효.방법 장2008년3월지2013년3월재원평시제일인민의원치료적57례만성반복발작형궤양성결장염환자분위치료조화대조조,대조조매천구복미사랍진,치료조채용풍료장위강효낭연합미사랍진.관찰량조환자적림상료효、림상증상완해정황、장경、조직학검사결과이급불량반응발생정황.결과 치료조림상료효、림상증상완해정황、장경、조직학검사결과균현저우우대조조(P<0.05);치료조총불량반응발생솔위32.26%,명현저우대조조(53.85%),량조비교차이유통계학의의(x2=9.506,P<0.05).결론 풍료장위강효낭연합미사랍진치료만성반복발작형궤양성결장염료효우우단용미사랍진,차안전성고,치득림상추엄응용.
Objective To investigate the clinical efficacy and safety of fengliaochangweikang capsule combined with mesalazine on patients with recurrent ulcerative colitis.Methods Fifty-seven cases of chronic recurrent ulcerative colitis from March 2008 to March 2012 in people' s hospital of Yuanping were divided into treatment group and control group.Patients in the control group were given oral mesalazine,patients in treatment group were given fengliaochangweikang capsule combined with mesalazine.The clinical efficacy,clinical symptoms,endoscopy,histological examination results and adverse reactions of both groups were observed.Results Clinical symptoms and the clinical effect of treatment group,remission,endoscopy,histological examination results were significantly superior to those in the control group(P < 0.05).The total incidence of adverse reaction was 32.26% in treatment group and it is significantly lower than that in control group (53.85%),the difference was statistically significant (x2 =9.506,P < 0.05).Conclusions Fengliaochangweikang capsule combined with mesalazine in treatment of chronic recurrent type of ulcerative colitis is better than single mesalazine,and the security is high,so it is worthy of clinical application.